Narcolepsy Market is Projected to Grow at a CAGR of 5.6% During the Forecast Period (2025-2034) Due to Increasing Disease Awareness, Improved Diagnosis, and Expanding Therapeutic Options | DelveInsight

Impact · against what's priced in

The article provides a positive long-term growth outlook for the narcolepsy market, but the specific catalysts for AXSM and TAK—the development of next-generation orexin and monoaminergic therapies—are standard pipeline expectations for these biotech firms. For the incumbents JAZ, AVDL, and HRMY, the report confirms the stability of their current therapeutic anchors without introducing new growth drivers.

TAK+0.50

No priced-in read yet